Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283653 · ClinicalTrials.gov registry record · NA
Dissemination and Implementation of DIGEST™ as an Evidence-based Measurement Tool for Dysphagia: A Randomized Implementation Trial
A NA study of Dysphagia and DIGEST, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT07283653: Recruiting NA study of Dysphagia and DIGEST, sponsored by M.D. Anderson Cancer Center.
NCT07283653 is a NA study of Dysphagia and DIGEST that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 85 participants, below the 170-participant average among 35 other Dysphagia trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283653, a NA study of Dysphagia and DIGEST, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
To improve swallowing outcomes in cancer through clinical implementation of the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST™) as an evidence-based practice (EBP) tool to grade pharyngeal dysphagia (difficulty swallowing) as a toxicity of cancer.
Conditions Studied
Interventions
- OTHER No intervention
- OTHER DIGEST Training Program
- OTHER DIGEST Training + Practice Facilitation
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2029-01-31 |
| Phase | NA |
What NCT07283653 shows while recruiting
NCT07283653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 170-participant average among 35 other Dysphagia trials with a reported enrollment target (50% lower).
The record links to 4 conditions, with Dysphagia appearing as the primary indexed condition, and to 3 interventions - of which No intervention is the first listed.
NCT07283653 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07283653 about?
NCT07283653 is a clinical study titled "Dissemination and Implementation of DIGEST™ as an Evidence-based Measurement Tool for Dysphagia: A Randomized Implementation Trial". To improve swallowing outcomes in cancer through clinical implementation of the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST™) as an evidence-based practice (EBP) tool to grade pharyngeal dysphagia (difficulty swallowing) as a toxicity of cancer.
What is the current status of trial NCT07283653?
This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2025-06-01. Estimated completion is 2029-01-31.
What conditions does trial NCT07283653 study?
This clinical trial studies the following conditions: Dysphagia, DIGEST, Evidence Based Measurement, Randomized Implementation.
What interventions are being tested in trial NCT07283653?
The interventions under investigation include: No intervention (OTHER), DIGEST Training Program (OTHER), DIGEST Training + Practice Facilitation (OTHER).
Who is sponsoring clinical trial NCT07283653?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283653 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysphagia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07283653's enrollment target sits among peer trials
85 17th of 35 higher than 19 of 35 other Dysphagia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dysphagia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia
RECRUITING · NA
-
Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study
RECRUITING · NA
-
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
RECRUITING · NA
-
External Pharyngeal Exerciser and Pharyngeal Phase of Swallowing
RECRUITING · NA
-
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
RECRUITING · NA
-
Dysphagia Study Using Novel Microphone Device
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI